FindMyKOL
Clinical trialNCT04601428TerminatedEarly phase 1Interventional

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

SponsorKoo Foundation Sun Yat-Sen Cancer CenterEnrollment12Hepatocellular Carcinoma (HCC)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent designed in the laboratory to block only tumor blood vessels, not blood vessels in the normal liver.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Taiwan
  • National Cheng Kung University Hospital (nckuh)

    Tainan, North Dist., Taiwan

  • Koo Foundation Sun Yat-Sen Cancer Center (kfsyscc)

    Taipei, Pei-Tou Dist., Taiwan

  • National Taiwan University Hospital (ntuh)

    Taipei, Zhongzheng Dist., Taiwan

  • Kfsyscc

    Taipei, Taiwan

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IA therapy of HCC with CSR02-Fab-TF
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Jan 2021
Primary completion
9 Apr 2026
Completion
9 Apr 2026
Last update posted
25 Aug 2026
Registered enrollment
12
Registry id
NCT04601428

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.